Will Pfizer Inc. (PFE) Stock Soar or Sink for the Rest of 2013?

Pfizer Inc. (NYSE:PFE) stock is off to a fine start in 2013. It might have gotten a bit ahead of itself earlier this year, but Pfizer stock has matched the S&P 500 for the year. For a large pharmaceutical company, you can’t ask for too much more.

PFE Chart

PFE data by YCharts.

Of course, past performance is rather meaningless as an investment thesis. The more important question is whether Pfizer Inc. (NYSE:PFE) stock will do well in the second half of the year.

Pfizer Inc. (NYSE:PFE)

Free bird

I like the slimmed-down version of Pfizer Inc. (NYSE:PFE) after it sold its nutrition business, and spun out its animal health business into Zoetis Inc (NYSE:ZTS).

The company allowed shareholders to trade in Pfizer stock for shares in Zoetis. More shareholders took Pfizer Inc. (NYSE:PFE) up on the deal than the company had shares of Zoetis Inc (NYSE:ZTS), resulting in a pro-rata exchange based on the number of shares investors were interested in exchanging.

After the exchange is complete, Pfizer Inc. (NYSE:PFE) won’t be able to include its portion of Zoetis’ earnings on its profit statement, but it’ll have a lower share count, which will more than make up for the lower earnings, resulting in higher earnings per share starting next year.

New drugs

With Pfizer shrunk down, the development of its pipeline becomes more important for the growth of Pfizer stock.

Of the recent drugs launched, Pfizer’s oral rheumatoid arthritis drug Xeljanz is probably the most important, given its blockbuster potential. In the first full quarter on the market, sales of Xeljanz were $11 million. Not a bad start, but a far cry from AbbVie Inc (NYSE:ABBV)‘s Humira, which had $4.3 billion in sales in the first quarter!

To reach that kind of sales number, Pfizer needs to expand Xeljanz into additional indications; Humira is approved for seven different autoimmune diseases. Pfizer is pushing Xeljanz in that direction, with phase 3 trials for psoriasis and psoriatic arthritis.

As an oral drug, Xeljanz should be able to trounce Humira and the other two anti-inflammatory mega blockbusters — Johnson & Johnson (NYSE:JNJ)‘s Remicade, and Amgen, Inc. (NASDAQ:AMGN)‘s Enbrel — because they have to be injected or infused. But doctors have a lot of experience with the three drugs, which all work on the same TNF-alpha pathway. It’s going to take time for Pfizer to get doctors comfortable with prescribing Xeljanz, which works through a different pathway called JAK.

Next up: Earnings

Investors will have to wait a month until the July 30 earnings announcement to get a better idea of where Pfizer stock might go in the second half. I think owners of Pfizer stock should be happy if the share price can get through the year matching the S&P500, while working through its post-Lipitor funk, especially since investors get to collect a dividend while they wait for better times.

The article Will Pfizer Stock Soar or Sink for the Rest of 2013? originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!